UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): February 2, 2015
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified
in its charter)
|
|
|
|
|
Florida |
|
001-33357 |
|
65-0643773 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
2 Snunit Street |
|
20100 |
Science Park, POB 455 |
|
|
Carmiel, Israel |
|
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant's telephone number, including
area code +972-4-988-9488
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events
On February 2, 2015, Protalix BioTherapeutics, Inc. (the “Company”)
issued a press release announcing that the Company has completed enrollment in its phase
I/II clinical trial of PRX-102 for the treatment of Fabry disease. A copy of the press release is attached hereto as Exhibit
99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
99.1 Press
release dated February 2, 2015
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PROTALIX BIOTHERAPEUTICS, INC. |
|
|
Date: February 2, 2015 |
By: |
/s/ Moshe Manor |
|
Name:
Title: |
Moshe Manor President
and Chief Executive Officer |
Exhibit 99.1
Protalix
BioTherapeutics Completes Enrollment in Phase I/II Clinical Trial
of PRX-102 for Fabry Disease
Interim
Efficacy and Safety Results to be Presented at WORLD Symposium
CARMIEL, Israel, February
2, 2015 -- Protalix BioTherapeutics, Inc. (NYSE
MKT:PLX) (TASE:PLX), announced today that the Company has completed enrollment in its phase I/II clinical trial of PRX-102 for
the treatment of Fabry disease. All patients that completed the trial have opted to continue to receive PRX-102 in an open-label
extension trial. PRX-102 is a proprietary plant cell-expressed, chemically modified recombinant alpha-galactosidase-A enzyme that
is designed to be a more stable enzyme than currently marketed enzyme replacement therapies for Fabry disease.
“The enthusiasm
surrounding this open label study continues to mount, as evidenced by physicians’ reactions to the interim data from the
0.2mg/kg dosing cohort,” said Mr. Moshe Manor, President and Chief Executive Officer of Protalix BioTherapeutics. “Not
only has PRX-102 shown benefits across all disease parameters, including remarkable results in pain, PRX-102 has also shown exciting
cardiac and kidney function at only six months of treatment. We look forward to reporting additional interim results, including
patient by patient data and cardiac and renal functions, at the WORLD Symposium.”
On February 12, 2015 at
10:45AM ET Dr. Ozlem Goker-Alpan, President and Chief Medical Officer of the Center for Clinical Trials, O&O Alpan, LLC., and
Director of the Lysosomal Research and Treatment Unit, will present interim results from the phase I/II trial in an oral presentation
titled, “Novel treatment for Fabry disease, IV administration of plant derived α-GAL-A enzyme phase 1/2 safety and
efficacy study: interim clinical report” at the Lysosomal Disease Network WORLD Symposium in Orlando, FL.
Additionally, the Company
expects to report interim results from the 1mg/kg cohort in the third quarter of 2015, and full top-line results from all dosing
cohorts in the fourth quarter of 2015. Management will request an end of Phase II meeting with the U.S. Food and Drug Administration
in the fourth quarter of 2015, and anticipates initiating a phase III pivotal trial in early 2016.
The phase I/II clinical
trial of PRX-102 is an open-label, dose-ranging study treating 18 naïve male and female patients with Fabry disease. The
three dose cohorts include dosage groups of 0.2 mg/kg, 1mg/kg and 2mg/kg with intravenous infusions of PRX-102 every two weeks,
with a six-month efficacy follow up period.
About
Protalix BioTherapeutics, Inc.
Protalix
is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through
its proprietary plant cell-based expression system, ProCellEx®. Protalix's unique expression system presents a proprietary
method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured
by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration(FDA) in May 2012,
by Israel's Ministry of Health in September 2012, by the Brazilian National Health Surveillance Agency (ANVISA)
in March 2013, by the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS) in April 2013,
by the Australian Therapeutic Goods Administration(TGA) in May 2014 and by the regulatory authorities of other countries. Marketing
applications for taliglucerase alfa have been filed in additional territories as well. Protalix has partnered with Pfizer
Inc. for the worldwide development and commercialization of taliglucerase alfa, excluding Israel and Brazil, where
Protalix retains full rights. Protalix's development pipeline includes the following product candidates: PRX-102, a modified
version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-112, an orally-delivered glucocerebrosidase
enzyme that is produced and encapsulated within carrot cells, also for the treatment of Gaucher disease; PRX-106, an orally-delivered
treatment for the treatment of Inflammatory Bowel Disease; PRX-110 for the treatment of Cystic Fibrosis; and others.
Forward-Looking
Statements
To
the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are
made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms "anticipate,"
"believe," "estimate," "expect," "plan" and "intend" and other words or phrases
of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known
and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements
made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and
development involve a high degree of risk. Factors that might cause material differences include, among others: failure or
delay in the commencement or completion of our preclinical and clinical trials which may be caused by several factors, including:
unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; slower than expected rates
of patient recruitment; inability to monitor patients adequately during or after treatment; inability or unwillingness of medical
investigators and institutional review boards to follow our clinical protocols; and lack of sufficient funding to finance clinical
trials; the risk that the results of the clinical trials of our product candidates will not support our claims of safety or efficacy,
that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected
characteristics; our dependence on performance by third party providers of services and supplies, including without limitation,
clinical trial services; delays in our preparation and filing of applications for regulatory approval; delays in the approval or
potential rejection of any applications we file with the FDA or other health regulatory authorities, and other risks
relating to the review process; the inherent risks and uncertainties in developing drug platforms and products of the type we are
developing; the impact of development of competing therapies and/or technologies by other companies and institutions; potential
product liability risks, and risks of securing adequate levels of product liability and other necessary insurance coverage; and
other factors described in our filings with the U.S. Securities and Exchange Commission. The statements in this release
are valid only as of the date hereof and we disclaim any obligation to update this information.
Investor
Contact
Marcy
Nanus
The Trout Group, LLC
646-378-2927
mnanus@troutgroup.com
Source: Protalix BioTherapeutics,
Inc.
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Apr 2023 to Apr 2024